Wu Jibin, Deng Rui, Yan Jianling, Zhu Baokang, Wang Jian, Xu Yinghua, Gui Shuiqing, Jin Xiaobao, Lu Xuemei
Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Life Science and Biopharmaceutics, Guangdong Pharmaceutical University, 280 Wai Huan Dong Road, Guangzhou Higher Education Mega Center, Guangzhou 510006, People's Republic of China.
Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, People's Republic of China.
iScience. 2023 Apr 29;26(5):106766. doi: 10.1016/j.isci.2023.106766. eCollection 2023 May 19.
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor, with a growing incidence and death rate worldwide. The aims and challenges of treating HCC include targeting the tumor, entering the tumor tissue, inhibiting the spread and growth of tumor cells. M27-39 is a small peptide isolated from the antimicrobial peptide cecropin (MDC), whereas HTPP is a liver-targeting, cell-penetrating peptide obtained from the circumsporozoite protein (CSP) of parasites. In this study, M27-39 was modified by HTPP to form M(27-39)-HTPP, which targeted tumor penetration to treat HCC. Here, we revealed that M(27-39)-HTPP had a good ability to target and penetrate the tumor, effectively limit the proliferation, migration, and invasion, and induce the apoptosis in HCC. Notably, M(27-39)-HTPP demonstrated good biosecurity when administered at therapeutic doses. Accordingly, M(27-39)-HTPP could be used as a new, safe, and efficient therapeutic peptide for HCC.
肝细胞癌（HCC）是一种常见的恶性肿瘤，在全球范围内其发病率和死亡率都在不断上升。治疗HCC的目标和挑战包括靶向肿瘤、进入肿瘤组织、抑制肿瘤细胞的扩散和生长。M27 - 39是一种从抗菌肽天蚕素（MDC）中分离出的小肽，而HTPP是一种从寄生虫环子孢子蛋白（CSP）中获得的肝脏靶向性细胞穿透肽。在本研究中，M27 - 39通过HTPP进行修饰形成M(27 - 39)-HTPP，其靶向肿瘤穿透以治疗HCC。在此，我们发现M(27 - 39)-HTPP具有良好的靶向和穿透肿瘤的能力，能有效限制HCC的增殖、迁移和侵袭，并诱导其凋亡。值得注意的是，M(27 - 39)-HTPP在治疗剂量下具有良好的生物安全性。因此，M(27 - 39)-HTPP可作为一种新型、安全且高效的HCC治疗肽。
